Bone Biologics
BBLG
5 hedge funds and large institutions have $69.7K invested in Bone Biologics in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
25% more funds holding
Funds holding: 4 → 5 (+1)
0.08% more ownership
Funds ownership: 0.79% → 0.87% (+0.08%)
22% less capital invested
Capital invested by funds: $89.1K → $69.7K (-$19.5K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$54.5K |
| 2 |
HF
HRT Financial
New York
|
+$28.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.54K |
| 4 |
MWA
MFA Wealth Advisors
Pittsburgh,
Pennsylvania
|
+$661 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$20 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$78.8K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$9 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $41.1K | +$54.5K | +5,518 | +5,518% |
|
|
HF
2
HRT Financial
New York
| $21K | +$28.8K | +2,920 | New |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $7.06K | +$2.54K | +257 | +36% |
|
|
MWA
4
MFA Wealth Advisors
Pittsburgh,
Pennsylvania
| $492 | +$661 | +67 | New |
|
|
5
Bank of America
Charlotte,
North Carolina
| $11 | +$20 | +2 | New |
|
|
AC
6
Armistice Capital
New York
| – | -$78.8K | -6,167 | Closed |
|
|
7
Wells Fargo
San Francisco,
California
| – | -$9 | -1 | Closed |
|
BBLG Hedge Fund Activity: Q2 2024 in Review
5 of the 6,926 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q2 2024, worth a combined $69.7K — down 22% from $89.1K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BBLG positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $54.5K. The largest seller was Armistice Capital, exiting entirely with an estimated $78.8K sold.
- 5 institutional investors held Bone Biologics (BBLG) as of Q2 2024, up from 4 in Q1 2024.
- Funds reported $69.7K of Bone Biologics stock for Q2 2024, down 22% quarter-over-quarter.
- 3 funds opened new Bone Biologics positions in Q2 2024 and 2 closed out, a net change of +1 holder.
- The largest Bone Biologics buyer in Q2 2024 was UBS Group, an estimated $54.5K added.
- The largest Bone Biologics seller in Q2 2024 was Armistice Capital, an estimated $78.8K sold.
Based on aggregated 13F filings for Q2 2024.